File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Comparison of Short-Term Clinical and Neurocognitive Outcome Between Atypical and Typical Antipsychotics in First Episode Schizophrenia

TitleComparison of Short-Term Clinical and Neurocognitive Outcome Between Atypical and Typical Antipsychotics in First Episode Schizophrenia
Authors
KeywordsMedical sciences
Psychiatry and neurology
Issue Date2002
PublisherCambridge University Press. The Journal's web site is located at http://journals.cambridge.org/action/displayJournal?jid=INS
Citation
The 30th Annual International Neuropsychological Society Conference, Toronto, Canada, 13-16 February 2002. In Journal of the International Neuropsychological Society, 2002, v. 8 n. 2, p. 180-181 How to Cite?
AbstractTreatment with atypical antipsychotics for patients with schizophrenia has been shown to have a beneficial effect on psychotic symptoms as well as a minimization of the medication side-effect profile. However, its effects for negative symptoms and neurocognitive impairments have not been consistently reported. The purpose of this study was to compare the short-term clinical and neurocognitive outcome between the first episode schizophrenic patients treated with atypical antipsychotic risperidone and those treated with conventional antipsychotic haloperidol in a randomized openlabel trial design. A total of 49 patients (29 patients in the risperidone group and 20 patients in the haloperidol group) were recruited. The Positive and Negative Symptoms Scale and High Royds Evaluation of Negativity Scale were used to assess psychotic symptoms. Neurocognitive function tests on attention, memory, and executive function were administered to patients upon admission and discharge. Medication side-effect and drop-out rate were also assessed. Despite the significant improvement of psychotic symptoms in both groups across the trial periods, risperidone did not demonstrate superiority in reduction of psychotic symptoms as well as medication side-effect profile as compared to haloperidol. However, patients in the risperidone group tended to show improvement in the Modified Wisconsin Card Sorting Test. The results indicate that positive symptomatic outcome is very good for first episode schizophrenia, whether treated with haloperidol or risperidone. Negative symptoms improved significantly but not completely in either group. Even though risperidone was used in a short-term treatment, it tends to improve general cognitive impairments in first episode schizophrenic patients as compared to haloperidol.
Persistent Identifierhttp://hdl.handle.net/10722/46980
ISSN
2023 Impact Factor: 2.6
2023 SCImago Journal Rankings: 1.028

 

DC FieldValueLanguage
dc.contributor.authorChen, Een_HK
dc.contributor.authorChan, RCKen_HK
dc.contributor.authorChan, Pen_HK
dc.contributor.authorKwong, Pen_HK
dc.contributor.authorChen, RYLen_HK
dc.date.accessioned2007-10-30T07:03:04Z-
dc.date.available2007-10-30T07:03:04Z-
dc.date.issued2002en_HK
dc.identifier.citationThe 30th Annual International Neuropsychological Society Conference, Toronto, Canada, 13-16 February 2002. In Journal of the International Neuropsychological Society, 2002, v. 8 n. 2, p. 180-181en_HK
dc.identifier.issn1355-6177en_HK
dc.identifier.urihttp://hdl.handle.net/10722/46980-
dc.description.abstractTreatment with atypical antipsychotics for patients with schizophrenia has been shown to have a beneficial effect on psychotic symptoms as well as a minimization of the medication side-effect profile. However, its effects for negative symptoms and neurocognitive impairments have not been consistently reported. The purpose of this study was to compare the short-term clinical and neurocognitive outcome between the first episode schizophrenic patients treated with atypical antipsychotic risperidone and those treated with conventional antipsychotic haloperidol in a randomized openlabel trial design. A total of 49 patients (29 patients in the risperidone group and 20 patients in the haloperidol group) were recruited. The Positive and Negative Symptoms Scale and High Royds Evaluation of Negativity Scale were used to assess psychotic symptoms. Neurocognitive function tests on attention, memory, and executive function were administered to patients upon admission and discharge. Medication side-effect and drop-out rate were also assessed. Despite the significant improvement of psychotic symptoms in both groups across the trial periods, risperidone did not demonstrate superiority in reduction of psychotic symptoms as well as medication side-effect profile as compared to haloperidol. However, patients in the risperidone group tended to show improvement in the Modified Wisconsin Card Sorting Test. The results indicate that positive symptomatic outcome is very good for first episode schizophrenia, whether treated with haloperidol or risperidone. Negative symptoms improved significantly but not completely in either group. Even though risperidone was used in a short-term treatment, it tends to improve general cognitive impairments in first episode schizophrenic patients as compared to haloperidol.-
dc.format.extent1488276 bytes-
dc.format.extent518103 bytes-
dc.format.extent2067 bytes-
dc.format.extent3474 bytes-
dc.format.mimetypeapplication/pdf-
dc.format.mimetypeapplication/pdf-
dc.format.mimetypetext/plain-
dc.format.mimetypetext/plain-
dc.languageengen_HK
dc.publisherCambridge University Press. The Journal's web site is located at http://journals.cambridge.org/action/displayJournal?jid=INSen_HK
dc.relation.ispartofJournal of the International Neuropsychological Society-
dc.subjectMedical sciencesen_HK
dc.subjectPsychiatry and neurologyen_HK
dc.titleComparison of Short-Term Clinical and Neurocognitive Outcome Between Atypical and Typical Antipsychotics in First Episode Schizophreniaen_HK
dc.typeConference_Paperen_HK
dc.description.naturelink_to_OA_fulltexten_HK
dc.identifier.doi10.1017/S1355617702822019-
dc.identifier.scopuseid_2-s2.0-0036484356-
dc.identifier.hkuros73354-
dc.identifier.volume8-
dc.identifier.issue2-
dc.identifier.spage180-
dc.identifier.epage181-
dc.identifier.issnl1355-6177-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats